November 1, 1994Current Opinion in Cardiology
Long-term vein graft patency
Key result
Surgical and pharmacological advances fail to resolve limited long-term SVG patency.
Why the study?
Despite widespread use of saphenous vein grafts in coronary artery bypass surgery, their limited long-term patency and optimal management strategies remain uncertain.
Population
Patients undergoing coronary artery bypass surgery
Comparison
Various strategies including surgical technique, antiplatelet/antithrombotic therapy, lipid lowering therapy, and alternative conduits
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
SVG patency limitations warrant caution in long-term CABG decisions; leaves open optimal revascularization strategies pending new RCTs.
Structured PICO
P
Population
Patients undergoing coronary artery bypass surgery
I
Intervention
Various strategies including surgical technique, antiplatelet/antithrombotic therapy, lipid lowering therapy, and alternative conduits
O
Outcome
Long-term vein graft patency
A comprehensive review emphasizing that despite various pharmacological and surgical strategies, long-term saphenous vein graft patency remains limited and requires further randomized trials.
Cite This Study
Martial G. Bourassa (1994) conducted a review in Coronary artery disease requiring bypass surgery. Long-term saphenous vein graft patency remains limited despite surgical and pharmacological advances, highlighting the need for further randomized trials comparing revascularization strategies.